"We address aggressive cancers that cannot be efficiently and safely treated today," said
Lapotko said quadrapeutics differs from other developmental cancer treatments in that it radically amplifies the intracellular effect of drugs and radiation only in cancer cells. The quadrapeutic effects are achieved by mechanical events - tiny, remotely triggered nano-explosions called "plasmonic nanobubbles." Plasmonic nanobubbles are non-stationary vapors that expand and burst inside cancer cells in nanoseconds in response to a short, low-energy laser pulse. Plasmonic nanobubbles act as a "mechanical drug" against cancer cells that cannot be surgically removed and are otherwise resistant to radiation and chemotherapy.
In prior studies, Lapotko showed he could use plasmonic nanobubbles alone to literally blow cells apart. In quadrapeutics, his team is using them to detect and kill cancer cells in three ways. In cancer cells that survive the initial explosions, the bursting nanobubbles greatly magnify the local doses of both chemotherapy drugs and radiation. All three effects - mechanical cell destruction, intracellular drug ejection and radiation amplification - occur only in cancer cells and do not harm vital healthy cells nearby.
To administer quadrapeutics, the team uses four clinically approved components: chemotherapy drugs, radiation, near-infrared laser pulses of low energy and colloidal gold.
"Quadrapeutics shifts the therapeutic paradigm for cancer from materials - drugs or nanoparticles - to mechanical events that are triggered on demand only inside cancer cells," Lapotko said. "Another strategic innovation is in complementing current macrotherapies with microtreatment. We literally bring surgery, chemotherapies and radiation therapies inside cancer cells."
The first component of quadrapeutics is a low dose of a clinically validated chemotherapy drug. The team tested two: doxorubicin and paclitaxel. In each case, the scientists used encapsulated versions of the drug that were tagged with antibodies designed to target cancer cells. Thanks to the magnifying effect of the plasmonic nanobubbles, the intracellular dose - the amount of the drug that is active inside cancer cells - is very high even when the patient receives only a few percent of the typical clinical dose.
The second component is an injectable solution of nontoxic gold colloids, tiny spheres of gold that are thousands of times smaller than a living cell. Quadrapeutics represents a new use of colloidal gold, which has been used for decades in the clinical treatment of arthritis. In quadrapeutics, the gold colloids are tagged with cancer-specific clinically approved antibodies that cause them to accumulate and cluster together inside cancer cells. These gold "nanoclusters" do nothing until activated by a laser pulse or radiation.
The third quadrapeutic component is a short near-infrared laser pulse that uses 1 million times less energy that a typical surgical laser. A standard endoscope delivers the laser pulse to the tumor, where the gold nanoclusters convert the laser energy into plasmonic nanobubbles.
Keywords for this news article include: Antibodies, Immunology, Blood Proteins, Immunoglobulins,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Americans Still Pessimistic Despite Economic Growth
- New Hershey's Logo Revealed
- Obama's Delay on Immigration Creates Uncertainty
- Obama on Labor Day: Don't Take Rights for Granted
- Buyer's Remorse on Common Core for Policymakers?
- Mexico's Pemex Forecasts 6.7% Drop in 2014 Crude Production
- California Passes First US Statewide Bag Ban
- Hip-Hop Takes Up Ferguson Cause
- American Airlines Back on Obitz
- Startups Offer Smartphone Banking Apps